dulaglutide + alpha-glucosidase inhibitor

**dulaglutide + alpha-glucosidase inhibitor** is a combination therapy for type 2 diabetes mellitus. Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, suppresses glucagon secretion, and slows gastric emptying, leading to improved glycemic control[2][3][6]. Alpha-glucosidase inhibitors (such as acarbose, miglitol, or voglibose) act by competitively inhibiting alpha-glucosidase enzymes in the small intestine, delaying the digestion and absorption of carbohydrates and thus reducing postprandial blood glucose rises[4]. This combination is used when monotherapy is insufficient for glycemic management, and its complementary mechanisms aim to lower both fasting and postprandial blood glucose, with a reduced risk for hypoglycemia and minimal impact on body weight[2][4][5].